IP Library › Granted Patent US 10,137,084
Granted Patent B2
US 10,137,084 · App. 15/091,791 · Granted Nov 27, 2018

Use of bethanechol for treatment of xerostomia

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,137,084
App. No.
15/091,791
Granted
Nov 27, 2018
Kind
B2
Abstract

Bethanechol is administered topically, for the treatment of xerostomia.

Claims (16)

1. A method of treating xerostomia, comprising buccal administration of bethanechol to a subject in need thereof.

2. The method of claim 1 , wherein the xerostomia is associated with head and neck cancer.

3. The method of claim 1 , wherein the xerostomia is associated with drug treatment.

4. The method of claim 1 , wherein the xerostomia is associated with cancer chemotherapy treatment.

5. The method of claim 1 , wherein the xerostomia is associated with Sjogren's syndrome.

6. The method of claim 1 , wherein the xerostomia is associated with late-stage cancer.

7. The method of claim 1 , wherein the bethanechol is in the form of bethanechol chloride.

8. The method of claim 1 , wherein the bethanechol is in the form of the S-enantiomer.

9. The method of claim 1 , wherein the bethanechol is maintained in the buccal cavity for between 30 seconds to 5 minutes.

10. The method of claim 9 , wherein the bethanechol is maintained in the buccal cavity for between 1 minute to 3 minutes.

11. The method of claim 9 , wherein the bethanechol is maintained in the buccal cavity for 2 minutes.

12. The method of claim 1 , wherein the bethanechol is swallowed.

13. The method of claim 1 , wherein the bethanechol is maintained in the buccal cavity for between 30 seconds to 5 minutes and is then swallowed.

14. The method of claim 1 , wherein the bethanechol is maintained in the buccal cavity for between 1 minute to 3 minutes and is then swallowed.

15. The method of claim 1 , wherein the bethanechol is maintained in the buccal cavity for 2 minutes and is then swallowed.

16. The method of claim 1 , wherein the bethanechol is administered more than once daily.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Apr 1, 2025
From: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
To: ACACIA PHARMA LIMITED
Reel/Frame 070698/0351 →
SECURITY INTEREST Recorded Apr 28, 2023
From: ACACIA PHARMA LIMITED
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 063476/0631 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 6, 2016
From: COOPER, NICOLA; GILBERT, JULIAN CLIVE; GRISTWOOD, ROBERT WILLIAM; WYLLIE, MICHAEL GRANT
To: ACACIA PHARMA LIMITED
Reel/Frame 038207/0598 →